UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...
Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates ...
Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global ...
It is administered through intratumoral route as a suspension and it is an oncolytic adenovirus consist of serotype 5 from serotype 35 (Ad5/35) which is modified to express CD40 ligand (CD40L) and ...
Similarly, the universities portfolio in Preclinical comprises 2 molecule. CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily.
Background: Currently, evidence regarding the causal relationship between primary immunodeficiency-related genes and varicella-zoster virus reactivation syndrome is limited and inconsistent. Therefore ...